{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:55Z","timestamp":1793145295075,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,4]],"date-time":"2027-08-04T00:00:00Z","timestamp":1817337600000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006426","name":"New Jersey Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011132","name":"Rutgers University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.molimm.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:18:00Z","timestamp":1785860280000},"page":"12-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The BTK inhibitor acalabrutinib inhibits the expression of PD-L1 on myeloid cells during inflammation"],"prefix":"10.1016","volume":"198","author":[{"given":"Sining","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith Shakarchi","family":"Warman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eris","family":"Spirollari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemmie","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung Ryu","family":"Tiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerendra","family":"Munugalavadla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori R.","family":"Covey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7338-3730","authenticated-orcid":false,"given":"Ping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2026.07.013_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 expression by NF-kappaB in cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.molimm.2026.07.013_bib2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/cancers11071037","article-title":"AP-1 transcription factors as regulators of immune responses in cancer","volume":"11","author":"Atsaves","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.molimm.2026.07.013_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1134\/S0026893322050028","article-title":"Murine models of chronic viral infections and associated cancers","volume":"56","author":"Avdoshina","year":"2022","journal-title":"Mol. Biol."},{"issue":"2","key":"10.1016\/j.molimm.2026.07.013_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molimm.2026.07.013_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2025.140839","article-title":"Impact of nanoplastics emitted from incineration of polyethylene plastic on THP-1 macrophage viability and immune function","volume":"501","author":"Bazina","year":"2026","journal-title":"J. Hazard. Mater."},{"issue":"5","key":"10.1016\/j.molimm.2026.07.013_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.hoc.2020.06.007","article-title":"Current role and emerging evidence for bruton tyrosine kinase inhibitors in the treatment of mantle cell lymphoma","volume":"34","author":"Bond","year":"2020","journal-title":"Hematol. Oncol. Clin. North. Am."},{"issue":"4","key":"10.1016\/j.molimm.2026.07.013_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.molimm.2026.07.013_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2010.039446","article-title":"Inflammation, the microenvironment and chronic lymphocytic leukemia","volume":"96","author":"Caligaris-Cappio","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.molimm.2026.07.013_bib9","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2596","article-title":"ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients","volume":"75","author":"Covey","year":"2015","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.molimm.2026.07.013_bib10","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.clinthera.2020.08.017","article-title":"Comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia: a systematic review and network meta-analysis","volume":"42","author":"Davids","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.molimm.2026.07.013_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fimmu.2019.00705","article-title":"NF-kappaB signaling in macrophages: dynamics, crosstalk, and signal integration","volume":"10","author":"Dorrington","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00018-023-05098-8","article-title":"Targeting the NF-kappaB pathway as a potential regulator of immune checkpoints in cancer immunotherapy","volume":"81","author":"Ebrahimi","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-014-0056-6","article-title":"Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes","volume":"7","author":"Edwards","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molimm.2026.07.013_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.leukres.2015.12.005","article-title":"Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells","volume":"41","author":"Edwards","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.molimm.2026.07.013_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/1471-2407-13-481","article-title":"N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma","volume":"13","author":"Edwards","year":"2013","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.molimm.2026.07.013_bib16","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.molimm.2026.07.013_bib17","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41375-021-01249-7","article-title":"Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL","volume":"35","author":"Ferrer","year":"2021","journal-title":"Leukemia"},{"issue":"40","key":"10.1016\/j.molimm.2026.07.013_bib18","doi-asserted-by":"crossref","first-page":"65968","DOI":"10.18632\/oncotarget.11782","article-title":"Ibrutinib modifies the function of monocyte\/macrophage population in chronic lymphocytic leukemia","volume":"7","author":"Fiorcari","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.molimm.2026.07.013_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/imm.12703","article-title":"Chronic infections with viruses or parasites: breaking bad to make good","volume":"150","author":"Godkin","year":"2017","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.molimm.2026.07.013_bib20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.4049\/jimmunol.2200563","article-title":"Upregulated expression of the IL-9 receptor on TRAF3-deficient B lymphocytes confers Ig isotype switching responsiveness to IL-9 in the presence of antigen receptor engagement and IL-4","volume":"210","author":"Gokhale","year":"2023","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-kappaB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.molimm.2026.07.013_bib22","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1177\/1078155220915956","article-title":"The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma","volume":"26","author":"Hanna","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.molimm.2026.07.013_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.molimm.2026.07.013_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-020-0715-5","article-title":"Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape","volume":"21","author":"Iovino","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.molimm.2026.07.013_bib25","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2147\/CMAR.S219570","article-title":"Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data","volume":"12","author":"Isaac","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"4","key":"10.1016\/j.molimm.2026.07.013_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cancers13040817","article-title":"BTK inhibition reverses MDSC-Mediated Immunosuppression and Enhances Response to anti-PDL1 therapy in neuroblastoma","volume":"13","author":"Ishfaq","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.molimm.2026.07.013_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ni0602-499","article-title":"Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848","volume":"3","author":"Jurk","year":"2002","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4049\/jimmunol.1401548","article-title":"Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice","volume":"194","author":"Lalani","year":"2015","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.molimm.2026.07.013_bib29","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","article-title":"B-cell receptor-mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signaling in diffuse large B-cell lymphoma","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2026.07.013_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-019-0139-8","article-title":"Frontline therapies for untreated chronic lymphoid leukemia","volume":"8","author":"Liu","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.molimm.2026.07.013_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-019-00635-7","article-title":"Inhibiting Bruton's tyrosine kinase in CLL and other B-cell malignancies","volume":"14","author":"Lucas","year":"2019","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085834","article-title":"Btk regulates macrophage polarization in response to lipopolysaccharide","volume":"9","author":"Ni Gabhann","year":"2014","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000587","article-title":"Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer","volume":"8","author":"Overman","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"issue":"24","key":"10.1016\/j.molimm.2026.07.013_bib35","doi-asserted-by":"crossref","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.molimm.2026.07.013_bib36","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3324\/haematol.2021.279560","article-title":"The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact","volume":"107","author":"Pinney","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s10020-018-0069-7","article-title":"Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia","volume":"25","author":"de Porto","year":"2019","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.molimm.2026.07.013_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semcdb.2008.06.004","article-title":"Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling","volume":"19","author":"Regis","year":"2008","journal-title":"Semin. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/hematology.2020000085","article-title":"Chemotherapy-free frontline therapy for CLL: is it worth it?","volume":"2020","author":"Rhodes","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","article-title":"The role of Bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"Crit. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.molimm.2026.07.013_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.critrevonc.2013.07.011","article-title":"Targeting inflammatory pathways in chronic lymphocytic leukemia","volume":"88","author":"Rozovski","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.molimm.2026.07.013_bib42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2013.02.007","article-title":"Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation","volume":"38","author":"Sade-Feldman","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.molimm.2026.07.013_bib43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1541-7786.MCR-22-0572","article-title":"Single-cell RNA-seq analysis of patient myeloid-derived suppressor cells and the response to inhibition of Bruton's tyrosine kinase","volume":"22","author":"Savardekar","year":"2024","journal-title":"Mol. Cancer Res."},{"issue":"21","key":"10.1016\/j.molimm.2026.07.013_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169927","article-title":"Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors","volume":"9","author":"Schwarz","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.molimm.2026.07.013_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110736","article-title":"Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide\/galactosamine-induced hepatic damage","volume":"131","author":"Shaker","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.molimm.2026.07.013_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.molimm.2026.07.013_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.molimm.2026.07.013_bib48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cmet.2017.06.001","article-title":"Specific and complex reprogramming of cellular metabolism in myeloid cells during innate immune responses","volume":"26","author":"Stienstra","year":"2017","journal-title":"Cell. Metab."},{"issue":"8","key":"10.1016\/j.molimm.2026.07.013_bib49","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","article-title":"Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment","volume":"76","author":"Stiff","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.molimm.2026.07.013_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/v13101951","article-title":"Chronic LCMV infection is fortified with versatile tactics to suppress host T cell immunity and establish viral persistence","volume":"13","author":"Studstill","year":"2021","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.molimm.2026.07.013_bib51","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1007\/s00262-023-03497-1","article-title":"BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy","volume":"72","author":"Sun","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.molimm.2026.07.013_bib52","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/1078-0432.CCR-21-2547","article-title":"Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof-of-concept study","volume":"28","author":"Taylor","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.molimm.2026.07.013_bib53","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.clinthera.2019.09.012","article-title":"Matching-adjusted indirect comparisons of the efficacy and safety of acalabrutinib versus other targeted therapies in relapsed\/refractory mantle cell lymphoma","volume":"41","author":"Telford","year":"2019","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.molimm.2026.07.013_bib54","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-020-0743-8","article-title":"Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells","volume":"122","author":"Varikuti","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molimm.2026.07.013_bib55","article-title":"Profound deficiencies in mature blood and bone marrow progenitor dendritic cells in Chronic Lymphocyticcytic Leukemia patients","author":"Welch","year":"2024","journal-title":"Res. Sq."},{"issue":"2","key":"10.1016\/j.molimm.2026.07.013_bib56","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.molimm.2026.07.013_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17121549","article-title":"Hierarchical delivery of anti-inflammatory compound and stem cells for chronic wounds","volume":"17","author":"Winkler","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.molimm.2026.07.013_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.molimm.2026.07.013_bib59","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1189\/jlb.0111044","article-title":"Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes","volume":"90","author":"Xie","year":"2011","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.molimm.2026.07.013_bib60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.immuni.2007.07.012","article-title":"Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs","volume":"27","author":"Xie","year":"2007","journal-title":"Immunity"},{"issue":"20","key":"10.1016\/j.molimm.2026.07.013_bib61","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1002\/cncr.33067","article-title":"A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.molimm.2026.07.013_bib62","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41419-022-05292-9","article-title":"PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.molimm.2026.07.013_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727531","article-title":"Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets - beyond B lymphocytes","volume":"9","author":"Zhu","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.molimm.2026.07.013_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.737943","article-title":"Clinical trials of the BTK inhibitors ibrutinib and acalabrutinib in human diseases beyond B cell malignancies","volume":"11","author":"Zhu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molimm.2026.07.013_bib65","article-title":"The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2026.07.013_bib66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4049\/jimmunol.2300541","article-title":"Plasmodium yoelii infection enhances the expansion of myeloid-derived suppressor cells via JAK\/STAT3 pathway","volume":"213","author":"Zhu","year":"2024","journal-title":"J. Immunol."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026001744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026001744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:03:46Z","timestamp":1788671026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589026001744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"alternative-id":["S0161589026001744"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2026.07.013","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The BTK inhibitor acalabrutinib inhibits the expression of PD-L1 on myeloid cells during inflammation","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}